Tvardi Therapeutics, Inc. (TVRD)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$1.85-4.64%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Tvardi is developing a novel cancer drug with potential. The company aims to maintain cash through Q4 2026 to fund trials. Phase 2 trial results expected in first half of 2026 could validate the drug. Past earnings beats show some operational progress.
Tvardi is loss-making with negative earnings expected to worsen. Analysts forecast about 31% revenue decline. Recent earnings misses and a 26% stock drop show risks. Cash runway may be tight without positive trial results.
The market expects about 31% revenue decline and worsening losses. Our view aligns with this cautious outlook given the lack of revenue and ongoing losses.
Breaks if: Cash runway falls short of funding operations through Q4 2026
Breaks if: EPS loss worsens beyond consensus estimates through FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity within the healthcare sector. The current thesis state is cautious, as the company has faced challenges with earnings and execution quality.
The market appears to have priced in a level of fragility due to weak execution quality, but it is not fully reflecting the potential turbulence ahead. Valuation is considered cheap compared to peers, indicating that expectations may be lower than what is typical for the sector.
Fundamentals are likely to remain fragile in the near term, especially with a high probability of an earnings miss. Management is focused on advancing clinical trials, but ongoing cash burn raises concerns about financial stability.
The thesis hinges on the outcomes of upcoming clinical trials and the overall health of the healthcare sector. Additionally, guidance from management and macroeconomic factors, such as job reports, will be crucial in shaping future performance.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company advanced TTI-109 development in ulcerative colitis. This aligns with management's objectives and supports the thesis. However, the latest earnings report showed a miss, which weakens the outlook.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Phase 2 trial results delayed beyond 1H 2026 or negative outcomes reported
Over the next 1 to 3 years, TVRD faces significant challenges that could impact its growth trajectory. Not investment advice.